KBio utilizes a pioneering platform known as RP3, which harnesses the power of plants as biofoundries to produce therapeutics and bioactive compounds at an unprecedented scale. This innovative approach to biologic manufacturing is designed to overcome the limitations of traditional methods, enabling the efficient and sustainable production of high-quality proteins derived from plant sources. By leveraging strategic global partnerships, KBio optimizes its platform through cutting-edge technologies, positioning itself at the forefront of plant-based manufacturing solutions.

The RP3 platform is particularly adept at addressing urgent public health challenges that require rapid development and large-scale production of biomolecules. This capability allows KBio to contribute significantly to health and medicine initiatives, offering plant-based solutions that are both versatile and impactful. The company's commitment to sustainability and efficiency in biologic manufacturing underscores its role as a leader in the emerging field of plant-powered solutions.

United States

KBio aims to create a new generation of biologics using its plant-based platform that has demonstrated the ability to create drug candidates at a fraction of the time and cost of conventional platforms. The Company is focused on developing novel product candidates in two core areas: 1) Antibody therapies for areas of high unmet need; and 2) Pandemic preparedness and response using its plant-based production system to create antibodies and vaccines in shorter timeframes than industry norms.
 
Formed in December 2021, KBio is a subsidiary of BAT with operations in the UK and U.S.

KBio

Company Details